Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.71B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.30M
Average 1.16M
XENE Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Xenon Pharmaceuticals Inc.NASDAQ: XENE
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses growth accelerates
Q3 FY2026 other income / expenses of $11.48M rose 87.6% year over year, ahead of the +15.2% change in trailing-twelve-month other income / expenses. Sequentially, it fell 3.0% from the prior quarter. Over 3 fiscal years it compounded at +93.5% a year.
Context
- Other income / expenses amounted to 375.7% of revenue in FY2025.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +87.6% holds above the trailing-twelve-month pace of +15.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 28.18M USD
- Year-over-year change
- -31.1%
- 4-year CAGR
- +304.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.18M | -31.1% |
| FY2024 | 2024-12-31 | 40.88M | +30.3% |
| FY2023 | 2023-12-31 | 31.37M | +706.8% |
| FY2022 | 2022-12-31 | 3.89M | +3602.9% |
| FY2021 | 2021-12-31 | 105K | — |
Other Income / Expenses vs competitors
How XENE compares with its peers on the latest reported figures
- XENE's LTM Sep 2026 other income / expenses of $35.81M is the 3rd highest of the 11 companies compared; the peer median is $9.8M.
- Its year-over-year change of +15.2% is the 3rd highest of 11, against a peer median of -38.8%.
- Over three fiscal years its annual growth of +93.5% compares with a peer median of +42.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.9M | -35.1% | — | 1.4% | |
| LTM Sep 2026 | $47.3M | +135.6% | +188.3% | — | |
| LTM Sep 2026 | $35.81M | +15.2% | +93.5% | — | |
| LTM Jun 2026 | $31.35M | -42.6% | +42.7% | 869.8% | |
| LTM Sep 2026 | $26.16M | -20.1% | +49.8% | 2.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $14.93M | +11.7% | — | 74.6% |
| LTM Dec 2025 | $4.67M | -45.3% | +14.3% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $745K | -95.5% | -4.3% | — |
| LTM Jun 2026 | -$2.54M | +86.5% | — | 0.3% | |
| LTM Jun 2026 | -$11.65M | -164.6% | — | 1.4% | |
| LTM Sep 2026 | -$698.22M | -233.0% | — | 14.8% | |
| Peer median (excluding XENE) | $9.8M | -38.8% | +42.7% | 2.2% | |
Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.44M | 9.43M | 0 | 0 | 7.5M |
| Cost of Revenue | 0 | 0 | 167.51M | 2.56M | 2.54M |
| Gross Profit | 18.44M | 9.43M | (167.51M) | (2.56M) | 4.96M |
| Gross Margin | 100.0% | 100.0% | — | — | 66.1% |
| Research & Development | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
| Selling, General & Admin | 21.97M | 32.81M | 46.54M | 68.9M | 79.63M |
| Operating Expenses | 97.43M | 138.58M | 46.54M | 276.74M | 378.03M |
| Depreciation & Amortization | 906K | 1.41M | 3.54M | 2.56M | 2.54M |
| EBITDA | (78.09M) | (127.74M) | (210.51M) | (235.86M) | (342.35M) |
| EBITDA Margin | -423.5% | -1354.0% | — | — | -4564.7% |
| Operating Income | (78.99M) | (129.14M) | (214.05M) | (279.3M) | (373.07M) |
| Operating Margin | -428.4% | -1368.9% | — | — | -4974.3% |
| Interest Income | 466K | 8.71M | 27.62M | 41.94M | 26.83M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 105K | 3.89M | 31.37M | 40.88M | 28.18M |
| Income Before Tax | (78.89M) | (125.26M) | (182.69M) | (238.42M) | (344.89M) |
| Pre-Tax Margin | -427.9% | -1327.7% | — | — | -4598.6% |
| Income Tax Expense | (6K) | 118K | (292K) | (4.09M) | 1.02M |
| Net Income | (78.88M) | (125.37M) | (182.39M) | (234.33M) | (345.91M) |
| Net Margin | -427.8% | -1328.9% | — | — | -4612.1% |
| EPS (Basic) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| EPS (Diluted) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| Weighted Avg Shares | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
| Weighted Avg Shares (Diluted) | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.